Editorial: Causes of Oocyte Aneuploidy and Infertility in Advanced Maternal Age and Emerging Therapeutic Approaches

Lori R. Bernstein1,2,3* and Nathan R. Treff4,5

1 Pregmama, LLC, Gaithersburg, MD, United States, 2 Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, United States, 3 Department of Veterinary Integrative Biosciences, Texas A&M College of Veterinary Medicine, College Station, TX, United States, 4 Genomic Prediction Inc., North Brunswick, NJ, United States, 5 Genomic Prediction Clinical Laboratory, North Brunswick, NJ, United States

Keywords: infertility, advanced maternal age, aneuploidy, preimplantation genetic testing, reactive oxygen species, endometriosis

Editorial on the Research Topic

Causes of Oocyte Aneuploidy and Infertility in Advanced Maternal Age and Emerging Therapeutic Approaches

Women of advanced maternal age (AMA, age ≥ 35) experience elevated rates of infertility, miscarriages and trisomic pregnancies (Ubaldi et al.). They also exhibit diminished ovarian reserve (DOR), as well as poor ovarian responses (POR) to gonadotropin stimulation in assisted reproduction (Fuentes et al.). Oocyte and embryo aneuploidy are primary causes of declining oocyte and embryo quality and diminished rates of pregnancy and livebirth in AMA women. Mechanisms that underlie these processes are thought to include cohesin dysfunction, telomere shortening, spindle instability, aberrant checkpoint control, reductions in rates of preimplantation embryo development to the blastocyst stage, age-related hormonal aberrations, and mitochondrial dysfunction (Ubaldi et al.; Fuentes et al.) (1). Some factors that reduce oocyte quality and embryo quality in AMA women may also be at play in the pathogenesis of endometriosis (Máté et al.). Current and emerging technological advances continue to be developed to treat and even prevent oocyte aneuploidy in patients with diminished oocyte and embryo quality. Here present an editorial summary of these themes in this article collection, along with some recent data drawn from additional relevant papers.

CAUSATIVE FACTORS

There have been recent advances in understanding molecular determinants of declining ovarian reserve and oocyte and embryo quality. Patterns of oocyte epigenetic modifications in oocytes, including DNA methylation and histone modifications in chromatin, undergo distinctive changes with maternal age (Chamani and Keefe). These changes may have causative roles in the increased aneuploidy of oocytes in AMA women. There also is mounting evidence that reactive oxygen species (ROS) adversely impact oocyte and embryo quality both in AMA women, and in women with endometriosis (Máté et al.) (2). ROS from endogenous and exogenous sources over time may be
drivers of molecular damage to oocyte and embryo chromosome segregation apparatus, as well as the molecular components of other organelles (e.g., mitochondria) in aging women, causing aneuploidy and other manifestations of poor oocyte quality (2). Retrograde menstruation occurs in women with endometriosis. This brings menstrual blood into proximity to the fallopian tubes and ovaries. As the refluxed blood undergoes natural degradation, intracellular contents are released from red blood cells. This markedly increases local concentrations of iron that drive formation of the powerful ROS hydroxyl radical, potentially damaging cellular structures of oocytes and embryos residing in the ovaries and/or fallopian tubes to worsen oocyte and embryo quality (Máte et al.).

Hormonal changes that occur with age are postulated to have significant detrimental effects on fertility in AMA women. Androgens induce survival and growth of small follicles and induce expression of FSH receptors in granulosa cells (3, 4). AMA and DOR/POR are associated with significant declines in serum androgens and sex hormone binding globulin (SHBG) among several POSOIDON study groups of infertile women with POR (Fuentes et al.). While correlative, these data are consistent with the notion that declining androgen production that occurs with age and follicular depletion may contribute to worsening fertility in POR patients.

FSH elevation has been shown to reduce endometrial receptivity, lowering implantation and pregnancy rates (5, 6). In studies employing the SAMP8 mouse model of female reproductive aging, midlife female mice have elevated FSH, higher rates of oocyte chromosome and spindle misalignments, diminished yield of ovulated eggs, and lower fertility, than young female mice (7). Treating the midlife mice with equine chorionic gonadotropin (eCG), a hormone with high FSH activity, lowers yield of viable ovulated oocytes, and increases rates of oocyte chromosome and spindle misalignments.

Activin is an endogenous molecule that induces elevation of serum FSH (8). The soluble recombinant fusion protein ActRIIB:Fc is termed an activin decoy receptor because it binds and sequesters activin, preventing its binding to cell surface activin receptors (9). Administration of ActRIIB:Fc to midlife SAMP8 female mice lowers their serum FSH to young levels, decreases rates of oocyte chromosome and spindle misalignments, raises yields of viable ovulated oocytes, and increases their fertility (1). These data support the hypothesis that FSH elevation and/or other activities of the activin signaling pathway promote oocyte aneuploidy and infertility in AMA mice.

CURRENT AND EMERGING METHODS FOR IMPROVING AMA REPRODUCTIVE SUCCESS STIMULATION PROTOCOLS

Various assisted reproductive technology (ART) hormonal stimulation protocols have been developed to increase pregnancy and delivery rates in AMA women (Ubaldi et al.). One approach is mathematical—increase the likelihood of pregnancy by maximizing gonadotropin dose to produce a high yield of embryos. Other REI practices operate under the concept that high-dose FSH may adversely impact oocyte and/or embryo quality. Thus, they perform “mild” or “natural” IVF cycles employing low or no FSH administration. This results in lower embryo yield than the high dose protocols. There may be a “Goldilocks” dose for each patient that optimizes her yield of high-quality embryos.

Embryo Selection

To date there are not established methods in humans for preventing oocyte and embryo aneuploidy. However, optimized stimulation protocols coupled with embryo karyotyping by preimplantation genetic testing (PGT-A) of biopsied embryos are employed to improve reproductive outcomes in AMA women. This is achieved by selecting euploid embryos for transfer while avoiding the transfer of aneuploid embryos (Poli et al.). The combination of IVF, embryo growth to the blastocyst stage, and biopsy of trophectoderm, are state-of-the-art practice by most IVF labs that perform PGT-A. Biopsying without damage to embryos requires specialized expertise not available to most IVF laboratories. Thus, evaluation of non-invasive procurement of chromosomal material from spent culture media to assess aneuploidy is under development. Procured samples are analyzed by a variety of means including PGT-A, and most recently MALDI-TOF mass spectrometry (Ubaldi et al.; Poli et al.) (10).

Testing to Determine Embryo Karyotype

Comprehensive chromosomal screening (CCS) with Next Generation Sequencing (NGS) and Single Nucleotide Polymorphism (SNP) analyses of day 5–6 trophectoderm biopsies are state-of-the-art PGT-A methods employed to quantitate copy number for all 24 human chromosomes (Ubaldi et al.; Poli et al.). A study by Neal et al. compared a large group of PGT-A patients to a retrospectively defined patient cohort that had undergone blastocyst transfers without prior PGT-A (mean patient age 36.0 ± 4.3) (11). PGT-A did not improve cumulative pregnancy rates, but it did improve pregnancy rates per transfer (pregnancy rates per retrieval were not reported), and it reduced time to pregnancy and rates of miscarriage. Several randomized clinical trials (RCTs) have tested the efficacy of PGT-A for improving pregnancy outcomes. Among other studies, some cited improvements, and others cited no improvements or inconclusive results for diverse clinical endpoints (Ubaldi et al.) (12–14). An RCT from 2020 showed that IVF patients undergoing PGT-A had fewer cycles culminating in embryo transfers than those who had IVF alone (15). Despite this drawback, AMA patients (but not young patients) given PGT-A in the study had higher likelihood of clinical pregnancy and livebirth and lower probability of miscarriage than those who did not. Patients in a recent RCT for AMA women with severe DOR/POR showed no improvement of livebirth rates, and only nominal improvement in miscarriage rates (16). Additional RCTs are needed that include more patients and focus on defined patient cohorts—e.g. specific age groups; good/poor responders; recurrent miscarriage; repeated implantation failure. This will
permit definitive conclusions regarding the efficacy of PGT-A in these diverse patient populations.

Development and testing of novel ancillary preimplantation embryo markers highly correlated with embryo quality and euploidy that are also underway, with the goal of selecting embryos that will increase pregnancy and livebirth rates. These include quantitative measurements of epigenetic landscape and transcriptomes (Poli et al.). Continuing advances are also being made in the realm of preimplantation genetic testing and selection of wild type embryos conceived by carriers of monogenic (PGT-M) and polygenic (PGT-P) mutations (Poli et al.; Treff et al.). PGT-M and PGT-P selection of wild-type embryos provides significant reduction in risks of disease inheritance. Coupled together, PGT-A, PGT-M, PGT-P, epigenetic, and transcriptosomal approaches hold promise to increase the rates of healthy livebirths for patients at high risk of adverse outcomes due to maternal age and genetic disease mutations.

**Donor and Cryopreserved Eggs and Embryos**

Health pregnancies for women of advanced maternal ages with severe DOR, POR and/or high aneuploidy rates in prior cycles are much more achievable using donated oocytes or embryos from third parties (Poli et al.). Pregnancy and live birth rates are quite high, although gametes are from other people. Women who anticipate a need to delay pregnancy and wish to use their own eggs to conceive biological offspring can freeze their eggs or embryos for future pregnancy attempts, with increasingly promising success rates when oocytes are utilized within several years after oocyte retrieval.

**Experimental Therapies**

Ovarian tissue banking is a developing technology for oocyte preservation until a future pregnancy is attempted (Ubaldi et al.). Nuclear transfer of spindle-chromosomal complexes, pronuclear or mitochondrial transfer, and chromosomal therapy are experimental approaches for improving reproductive parameters in infertile AMA patients. Their efficacy is not yet known. Generation of biologically “young” oocytes from putative oogonial stem cells (OSCs) has been under investigation for some time, but the existence of human OSCs has been called into question by investigators unable to reproduce OSC isolation protocols.

A review of detrimental effects of ROS in adversely impacting oocyte and embryo quality is provided by Máté et al. in this article collection. ROS has significant adverse impacts on spindle assembly and integrity. Various antioxidant treatments show effectiveness in animal studies to protect oocytes and embryos from spindle aberrations and aneuploidy, including resveratrol, N-acetyl cysteine, vitamins C and E, and other molecules. Melatonin is a potent antioxidant molecule that decreases mouse oocyte spindle aberrations, increases mitochondrial DNA copy number, and increases blastocyst quality. In human trials melatonin improved ovarian response and embryo quality compared to controls (17).

Coenzyme Q10 (CoQ10) has potent antioxidant activity. Also, it promotes mitochondrial ATP production in its capacity as a proton transport protein. CoQ10 treatment restores mitochondrial function, cumulus cell function, and oocyte spindle integrity and fertility in reproductively aged female mice (18, 19). Infertile AMA IVF patients given CoQ10 trended toward increased embryo quality and decreased aneuploidy compared to the placebo group, although in this underpowered study the differences were not statistically significant (20). In patients <35 with DOR, women in the CoQ10 group had a better ovarian response and embryo quality than those in the placebo group, with statistically insignificant trends toward increased live birth and cumulative live birth rates (21). Similar treatments employing antioxidants and molecules that boost mitochondrial function are envisioned to treat endometriosis (Máté et al.).

Several approaches have been attempted and are under development to improve AMA fertility by correcting hormonal deficits. Mixed results have been obtained using therapies that employ growth hormone, dihydroepiandrosterone (DHEA), or testosterone (22, 23). As described above, activin receptor pathway blockade in midlife mice by administration of the activin decoy receptor ActRIIB:Fc lowers FSH to young levels, increases egg yield, prevents oocyte chromosome and spindle misalignments, and increases litter sizes (1). Manipulation of maternal hormone levels and pathways mediated by activin receptors provide promising avenues for developing new therapies to prevent oocyte and fetal aneuploidy and improve fertility in AMA women.

**AUTHOR CONTRIBUTIONS**

LB and NT wrote the manuscript. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Bernstein LR, Mackenzie AC, Lee SJ, Chaffin CL, Merchenthaler I. Activin decoy receptor ActRIIB:Fc lowers FSH and therapeutically restores oocyte yield, prevents oocyte chromosome misalignments and spindle aberrations, and increases fertility in midlife female SAMP8 mice. *Endocrinol* (2016) 157:1234–47. doi: 10.1210/en.2015-1702

2. Sasaki H, Hamatani T, Kamijo S, Iwai M, Kobanawa M, Ogawa S, et al. Impact of oxidative stress on age-associated decline in oocyte developmental competence. *Front Endocrinol* (2019) 10:811. doi: 10.3389/fendo.2019.00811

3. Vendoka KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. *J Clin Invest* (1998) 101:2622–9. doi: 10.1172/JCI2081

4. Weil S, Vendoka K, Zhou J, Bondy CA. Androgens and follicle-stimulating hormone interactions in primate ovarian follicle development. *J Clin Endocrinol Metab* (1999) 84:295–6. doi: 10.1210/jcem.84.8.5929

5. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C, Thomas S. Evidence of impaired endometrial receptivity after ovarian stimulation for *in vitro* fertilization: a prospective randomized trial comparing fresh and frozen-
thawed embryo transfer in normal responders. Fertil Steril (2011) 96:344–8. doi: 10.1016/j.fertnstert.2011.05.050
6. Zhang D, Li J, Xu G, Zhang R, Zhou C, Qian Y, et al. Follicle-stimulating hormone promotes age-related endometrial atrophy through cross-talk with transforming growth factor beta signal transduction pathway. Aging Cell (2015) 14:284–7. doi: 10.1111/ace.12278
7. Bernstein LR, Mackenzie AC, Kraemer DC, Morley JE, Farr S, Chaffin CL, et al. Shortened estrous cycle length, increased FSH levels, FSH variance, oocyte spindle aberrations, and early declining fertility in aging senescence-accelerated mouse prone-8 (SAMP8) mice: concomitant characteristics of human midlife female reproductive aging. Endocrinol (2014) 155:2287–300. doi: 10.1210/en.2013-2153
8. Schang G, Ongaro L, Schultz H, Wang Y, Zhou X, Brulé E, et al. Murine FSH Production Depends on the Activin Type II Receptors ACVR2A and ACVR2B. Endocrinol (2020) 161(7):bqua056. doi: 10.1210/endoc/bqua056
9. Sako D, Grinberg AV, Liu J, Davies MV, Castonguay R, Maniatis S, et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type Ib. J Biol Chem (2010) 285:21037–48. doi: 10.1074/jbc.M110.114959
10. Pais RJ, Sharara F, Zmuidznieks R, Butler S, Keshavarz S, Iles R. Bioinformatic identification of euploid and aneuploid embryo secretome signatures in IVF culture media based on MALDI-ToF mass spectrometry. J Assist Reprod Genet (2020) 37:2189–98. doi: 10.1007/s10815-020-01890-8
11. Neal SA, Morin SJ, Franziali JM, Goodman LR, Juneau CR, Forman EJ, et al. Preimplantation genetic testing for aneuploidy is cost-effective, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage. Fertil Steril (2018) 110:11896–904. doi: 10.1016/j.fertnstert.2018.06.021
12. Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion. Fertil Steril (2018) 109:429–36. doi: 10.1016/j.fertnstert.2018.01.002
13. Kemper JM, Vollenhoven BJ, Talmor AJ. Preimplantation genetic testing for aneuploidy: a review. Obstet Gynecol Surv (2019) 74:727–37. doi: 10.1097/OGX.0000000000000737
14. Kemper JM, Wang R, Rolnik DL, Mol BW. Preimplantation genetic testing for aneuploidy: are we examining the correct outcomes? Hum Reprod (2020) 35:2408–12. doi: 10.1093/humrep/deaa224
15. Haviland Mf, Murphy LA, Modest AM, Fox MP, Wise LA, Nillni YI, et al. Comparison of pregnancy outcomes following preimplantation genetic testing for aneuploidy using a matched propensity score design. Hum Reprod (2020) 35:2356–64. doi: 10.1093/humrep/deaa161
16. Deng J, Hong HY, Zhao Q, Nadgauda A, Ashrafian S, Behr B, et al. Preimplantation genetic testing for aneuploidy in poor ovarian responders with four or fewer oocytes retrieved. J Assist Reprod Genet (2020) 37:1147–54. doi: 10.1007/s10815-020-01765-y
17. Tamura H, Jozaki M, Tanabe M, Shirafuta Y, Mihara Y, Shinagawa M, et al. Importance of melatonin in assisted reproductive technology and ovarian aging. Int J Mol Sci (2020) 21:1135. doi: 10.3390/jms2101135
18. Ben-Meir A, Burstein EA, Chong AJ, Wong E, Vayorska T, Naranian T, et al. Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging. Aging Cell (2015) 14:887–95. doi: 10.1111/ acel.12368
19. Ben-Meir A, Kim K, McQuaid R, Esfandiari N, Bentov Y, Casper RF, et al. Co-Enzyme Q10 supplementation rescues cumulus cells dysfunction in a maternal aging model. Antioxidas (Basel) (2019) 8:58. doi: 10.3390/ antiox8030058
20. Bentov Y, Hannam T, Jurisicova A, Esfandiari N, Casper RF. Coenzyme Q10 supplementation and oocyte aneuploidy in women undergoing IVF–ICSI treatment. Clin Med Insights Reprod Health (2014) 8:31–6. doi: 10.4137/ CMRH.S14681
21. Xu Y, Nisenblat V, Lu C, Li R, Qiao J, Zhen X, et al. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. Reprod Biol Endocrinol (2018) 16:29. doi: 10.1186/s12958-018-0343-0
22. Yovich JL, Regan SL, Zaidi S, Keane KN. The concept of growth hormone deficiency affecting clinical prognosis in IVF. Front Endocrinol (Lausanne) (2019) 10:650:650. doi: 10.3389/fendo.2019.00650
23. Lassl K, Freisleben NLC, Wissing ML, Petersen KB, Holt MD, Mamsen LS, et al. Biological and clinical rationale for androgen priming in ovarian stimulation. Front Endocrinol (Lausanne) (2020) 11:627. doi: 10.3389/ fendo.2020.00627

Conflict of Interest: LB is Founder and Chief Scientific Officer of Pregmama, LLC. NT is Founder of Genomic Prediction Inc. and Genomic Prediction Clinical Laboratory.

Copyright © 2021 Bernstein and Treff. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.